• Explore /
  • Poster
  • / Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

Abstract Poster

Authors

Wungki Park

Wungki Park

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

Wungki Park , Eileen Mary O'Reilly , Junji Furuse , Chung-Pin Li , Do-Youn Oh , Rocio Garcia-Carbonero , Gaël Roth , Ho-Jin Lee , Futoshi Kunieda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT03816163

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4186)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4186

Abstract #

TPS4186

Poster Bd #

158a

Abstract Disclosures

Similar Posters

First Author: Wungki Park

First Author: Wungki Park

First Author: John Ebben

First Author: Benedikt Westphalen